Rachel Sachs

Rachel Sachs


Associate Professor of Law

Contact Information
Media Contact

Sachs is a renowned expert on health policy and drug law. She is a scholar of innovation policy whose work explores the interaction of intellectual property law, food and drug regulation and health law. Her work explores problems of innovation and access to new health care technologies. Sachs’ scholarship has or will have appeared in journals that include the Michigan Law Review, the Minnesota Law Review, the Harvard Law Review, the New England Journal of Medicine, and the Journal of the American Medical Association.

In the media

The Drug That Could Break American Health Care

Aduhelm, the first new Alzheimer’s drug in 18 years, may not work. But states and Medicare might pay billions of dollars for it anyway, argues the School of Law’s Rachel Sachs, an expert on drug pricing.

Stories

Sachs testifies before House committee

Sachs testifies before House committee

Rachel Sachs, an expert on drug pricing at the School of Law, testified May 4 before the House Committee on Energy & Commerce about lowering prescription drug costs.
WHO withdrawal may not be legal

WHO withdrawal may not be legal

President Donald Trump announced July 7 that the United States has officially begun to withdraw from the World Health Organization. Trump may or may not have the authority to do so, says an expert on health law at Washington University in St. Louis.
WashU Expert: Coronavirus failures suggest problem with innovation policy

WashU Expert: Coronavirus failures suggest problem with innovation policy

All of the issues surrounding COVID-19 trace back to a single legal stream, says an expert on drug policy and health law at Washington University in St. Louis. The lack of diagnostic testing. The lagging development and distribution of personal protective equipment. Shortages of ventilators. Finding prescription medication to treat the disease. They all are related by law and policy.
Prescription drug affordability

Prescription drug affordability

A final judgment invalidating the entire Affordable Care Act as unconstitutional would not only harm those in the individual market or Medicaid expansion—but would also jeopardize the ability of even more Americans to afford their prescription drugs.
WashU Expert: Budget provides insight into Trump Administration drug policy

WashU Expert: Budget provides insight into Trump Administration drug policy

During his first year in office, President Donald Trump spoke about high drug prices but took little action to address the problem. His budget proposal, released this week, does lay out a strategy — though what is most notable is not what’s included, but rather what is missing. Rachel Sachs, an expert on drug pricing and policy at Washington University in St. Louis, weighs in.
Drug policy: The year in review, and the year ahead

Drug policy: The year in review, and the year ahead

Last year was an unquestionably busy time for health care news of all kinds. Media and policy coverage rightly focused on the many attempts to repeal the Affordable Care Act, but it was also an eventful year in news for those of us who focus on prescription drug policy. In this post, I review five of the biggest drug policy developments of the past year, and look ahead to five issues I expect to make headlines in 2018.
WashU Expert: Incentivizing new uses for off-patent drugs

WashU Expert: Incentivizing new uses for off-patent drugs

Generic medications could be an effective way to improve health outcomes while lowering costs, but the existing drug patent system is poorly designed to motivate such discoveries, says an expert on health law at Washington University in St. Louis.
Be very, very concerned about what Allergan just did

Be very, very concerned about what Allergan just did

Yesterday, it was announced that Allergan had transferred the ownership of the patents on its billion-dollar drug Restasis, used for the treatment of chronic dry eye, to the Saint Regis Mohawk Tribe. The Tribe then exclusively licensed the drug back to Allergan, in exchange for tens of millions of dollars in both licensing and royalty fees. Although it may not sound like it, this transfer is potentially huge news in the drug pricing world. It is also extremely complex, and its full implications have yet to be determined.
WashU Expert: Trump has no clear plan for reducing drug prices

WashU Expert: Trump has no clear plan for reducing drug prices

Despite announcing in his first press conference that he would deal with a pharmaceutical industry “getting away with murder,” President-elect Donald Trump doesn’t seem to have a clear path for how he will reduce drug prices, said Rachel Sachs, associate professor of law and expert on drug regulation and health law.
WashU Expert: Cures Act’s controversy continues

WashU Expert: Cures Act’s controversy continues

The 21st Century Cures Act, the vast bill aimed at bolstering medical research and revamping the way drugs are approved, is a step in the right direction but is far from perfect, says an expert on the health care industry at the School of Law at Washington University in St. Louis.